APR-246
APR-407
Phase 2 small_molecule completed
Quick answer
APR-246 for Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 is a Phase 2 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aprea Therapeutics
- Indication
- Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed